Tobacco smoke and cardiovascular risk: A call for continued efforts to reduce exposure

Current Opinion in Cardiology

Volumn 26, Issue 5, 2011, Pages 424-428

  Frey, Paul ^a   Waters, David D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

cardiovascular risk; secondhand smoke; smoking

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TOBACCO SMOKE;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; ENVIRONMENTAL EXPOSURE; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; PASSIVE SMOKING; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; UNITED STATES;

CARDIOVASCULAR DISEASES; HUMANS; INHALATION EXPOSURE; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO SMOKE POLLUTION;

EID: 80051800343     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328349683d     Document Type: Review

References (43)

1. Centers for Disease Control and Prevention. Vital signs: Current cigarette smoking among adults aged >or=18 years - United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1135-1140. Most recent data from the Centers for Disease Control and Prevention on the demographics and prevalence of smoking in the United States.
2. Centers for Disease Control and Prevention. Cigarette use among high school students: United States, 1991-2009. MMWR Morb Mortal Wkly Rep 2010; 59:797-801. Using data obtained from the Youth Risk Behavior Survey, the Center for Disease Control and Prevention provides an analysis on the trends in smoking patterns among high school students in the United States.
3. Gu D, Kelly TN, Wu X, et al. Mortality attributable to smoking in China. N Engl J Med 2009; 360:150-159.
4. Hardoon SL, Whincup PH, Lennon LT, et al. How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population- based study. Circulation 2008; 117:598-604.
5. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356:2388-2398.
6. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:937-952.
7. Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137:494-500.
8. Vlietstra RE, Kronmal RA, Oberman A, et al. Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease. Report from the CASS registry. JAMA 1986; 255:1023-1027.
9. Goldenberg I, Jonas M, Tenenbaum A, et al. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 2003; 163:2301-2305.
10. Hasdai D, Garratt KN, Grill DE, et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336:755-761.
11. van Domburg RT, Meeter K, van Berkel DF, et al. Smoking cessation reduces mortality after coronary artery bypass surgery: A 20-year follow-up study. J Am Coll Cardiol 2000; 36:878-883.
12. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003; 290:86-97.
13. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004; 95:217-223.
14. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92:2432-2436.
15. Burghuber OC, Punzengruber C, Sinzinger H, et al. Platelet sensitivity to prostacyclin in smokers and nonsmokers. Chest 1986; 90:34-38.
16. Obi C, Wysokinski W, Karnicki K, et al. Inhibition of platelet-rich arterial thrombus in vivo: Acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol 2009; 29:1271-1276.
17. Chelland Campbell S, Moffatt RJ, Stamford BA. Smoking and smoking cessation: The relationship between cardiovascular disease and lipoprotein metabolism - a review. Atherosclerosis 2008; 201:225-235.
18. Edwards JE, Moore RA. Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003; 4:18.
19. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363-2372.
20. Frey P, Waters DD, DeMicco DA, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011; 107:145-150. This study demonstrates the continued risk of CHD with tobacco use despite contemporary pharmacologic treatment of CHD including intensive lipid-lowering therapy.
21. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
22. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005; 294:2437-2445.
23. Johnson HM, Gossett LK, Piper ME, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2010; 55:1988-1995. Demonstrates smoking cessation yields objective improvements on secondary endpoints, namely endothelial function as assessed by FMD, at 1 year. As endothelial dysfunction helps predict future cardiovascular events, improvement of FMD has important clinical implications.
24. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109 (23 Suppl 1):III27-III32.
25. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
26. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation 2005; 111:363-368.
27. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121:750-758. This paper investigates a contemporary cohort of individuals after an acute ischemic syndrome and examines the influence of behavioral interventions on short-term (6-month) rates of cardiovascular events. Importantly, recent quitters of smoking after an acute ischemic syndrome had significantly decreased odds of MI compared with persistent smokers. This demonstrates that, in a contemporary study population treated with up-to-date pharmacologic interventions, smoking cessation can yield rapid reductions in clinically important endpoints as soon as 6 months.
28. Schane RE, Glantz SA, Ling PM. Nondaily and social smoking: An increasingly prevalent pattern. Arch Intern Med 2009; 169:1742-1744.
29. Schane RE, Ling PM, Glantz SA. Health effects of light and intermittent smoking: A review. Circulation 2010; 121:1518-1522. A comprehensive and systematic review of the literature and data describing the health effects of light and intermittent smoking.
30. Moran S, Wechsler H, Rigotti NA. Social smoking among US college students. Pediatrics 2004; 114:1028-1034.
31. Fergusson DM, Horwood LJ. Transitions to cigarette smoking during adolescence. Addict Behav 1995; 20:627-642.
32. Schane RE, Glantz SA, Ling PM. Social smoking implications for public health, clinical practice, and intervention research. Am J Prev Med 2009; 37:124-131.
33. Levy DE, Biener L, Rigotti NA. The natural history of light smokers: A population-based cohort study. Nicotine Tob Res 2009; 11:156-163.
34. Hassmiller KM, Warner KE, Mendez D, et al. Nondaily smokers: Who are they? Am J Public Health 2003; 93:1321-1327.
35. Pope CA 3rd, Burnett RT, Krewski D, et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: Shape of the exposure-response relationship. Circulation 2009; 120:941-948.
36. Brook RD, Rajagopalan S, Pope CA 3rd, et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010; 121:2331-2378. This is a scientific consensus statement from the American Heart Association concluding that fine particulate matter air pollution contributes to cardiovascular morbidity and mortality. It serves as an expert opinion on this topic and a well referenced review on the most recent data pertaining to this subject.
37. Committee on Secondhand Smoke Exposure and Acute Coronary Events; Institute of Medicine. Secondhand smoke exposure and cardiovascular effects: Making sense of the evidence. 2009. http://www.iom.edu/Reports/ 2009/Secondhand-Smoke-Exposure-and-Cardiovascular-Effects-Making- Sense-of-the-Evidence.aspx. [Accessed 13 April 2011]
38. Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: Sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol 2008; 51:1760-1771.
39. Centers for Disease Control and Prevention. Vital signs: Nonsmokers' exposure to secondhand smoke: United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2010; 59:1141-1146.
40. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: Nearly as large as smoking. Circulation 2005; 111:2684-2698.
41. US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion. The health consequences of involuntary exposure to tobacco smoke: A report of the Surgeon General. Atlanta, GA2006. Report No. O2NLM: WA 754 H4325 2006.
42. Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: A systematic review and meta-analysis. J Am Coll Cardiol 2009; 54:1249-1255.
43. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: Before and after study. BMJ 2004; 328:977-980.